Trevi Therapeutics appoints David Hastings as chief financial officer

Trevi Therapeutics Inc. (NASDAQ: TRVI) announced that David Hastings will join the company as chief financial officer effective January 6, 2026. The New Haven, Connecticut-based clinical-stage biopharmaceutical company develops Haduvio, an investigational therapy for chronic cough treatment.

Hastings brings over 25 years of financial leadership experience in public life sciences and biopharmaceutical companies. Throughout his career, he has raised over $2 billion in equity and debt financing, according to the company's statement.

Most recently, Hastings served as chief financial officer at Arbutus from June 2018 until March 2025. He previously held the CFO position at Unilife from 2015 to 2017 and spent 11 years as CFO and executive vice president at Incyte from 2003 to 2014. During his tenure at Incyte, he oversaw the company's transition from research and development to commercialization following the launch of Jakafi.

Hastings also served as vice president, CFO and treasurer at ArQule Inc., where he contributed to the company's transition into a drug discovery and development organization. He currently serves as a board member and chair of the audit committee at Scynexis Inc.

"His proven track record and experience as we transition into Phase 3 development and beyond will be critical as we continue to advance Haduvio for the treatment of chronic cough," said Jennifer Good, president and CEO of Trevi Therapeutics.

Trevi Therapeutics develops Haduvio, an oral nalbuphine extended-release therapy, for treating chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. The company states that Haduvio is the first investigational therapy to show statistically significant reduction in cough frequency in clinical trials across both patient populations.

You May Also Be Interested In

• Definitive Healthcare names Clay Ritchey as new CEO
• Diversified Energy to acquire Birch for $1.8B in Permian expansion
• DEFSEC Technologies (DFSC) files for 4.05M share offering by selling stockholders